Paul A. M. van Leeuwen

Paul A. M. van Leeuwen

Auto-generated profile, based on publicly available information

Paul A. M. van Leeuwen

Department of Surgery, VU university medical center, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
BMBarbara Suzanne van der Meij
Barbara Suzanne van der Meij
JLJacqueline A. E. Langius
Jacqueline A. E. Langius
ESEgbert F. Smit
Egbert F. Smit
MSMarieke D. Spreeuwenberg
Marieke D. Spreeuwenberg
BBB. Mary E. von Blomberg
B. Mary E. von Blomberg
PLPaul A. M. van Leeuwen
Paul A. M. van Leeuwen
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), (n-3) fatty acids from fish oil, have immune-modulating effects and may improve nutrition

23 May 2007 in The Journal of Physiology
Verified
Journal Article
Closed access
MPMarcel C. G. Van De Poll
Marcel C. G. Van De Poll
GLGerdien C. Ligthart‐Melis
Gerdien C. Ligthart‐Melis
PBPetra G. Boelens
Petra G. Boelens
NDNicolaas E. P. Deutz
Nicolaas E. P. Deutz
PLPaul A. M. Van Leeuwen
Paul A. M. Van Leeuwen
CDCornelis H. C. Dejong
Cornelis H. C. Dejong

11 January 2012 in European Journal of Clinical Nutrition
Verified
Journal Article
Open access
BMBarbara Suzanne van der Meij
Barbara Suzanne van der Meij
JLJ A E Langius
J A E Langius
MSM D Spreeuwenberg
M D Spreeuwenberg
SSS M Slootmaker
S M Slootmaker
MPM A Paul
M A Paul
PLP A M van Leeuwen
P A M van Leeuwen
Background/Objectives: Subjects/Methods: Results: Conclusion:

1 July 2017 in Clinical Breast Cancer
Verified
Journal Article
Closed access
MBMyrte C. de Boer
Myrte C. de Boer
EWElisabeth A. Wörner
Elisabeth A. Wörner
DVDiede Verlaan
Diede Verlaan
PLPaul A.M. van Leeuwen
Paul A.M. van Leeuwen

1 May 2008 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
GLGerdien C Ligthart-Melis
Gerdien C Ligthart-Melis
MPMarcel Cg van de Poll
Marcel Cg van de Poll
PBPetra G Boelens
Petra G Boelens
CDCornelis Hc Dejong
Cornelis Hc Dejong
NDNicolaas Ep Deutz
Nicolaas Ep Deutz
PLPaul Am van Leeuwen
Paul Am van Leeuwen
Background: A metabolic relation exists between glutamine and arginine, 2 amino acids with properties that enhance the recovery of seriously ill patients. It is possible that glutamine exerts part of its beneficial effects by enhancing the availability of arginine. Objectives: We aimed to quantify under postabsorptive conditions the metabolic pathway of plasma glutamine into arginine via the intermediate citrulline and to establish the contribution of the kidneys to the synthesis of arginine. Design: The study was conducted in patients during surgery. The metabolism of glutamine, citrulline, and arginine was studied by using intravenous administration of stable isotope tracers of the amino acids. Results were interpreted by using established equations. Parametric tests were used to test and correlate results. P < 0.05 was regarded as significant. Results: Mean (±SE) whole-body plasma turnover rates of glutamine, citrulline, and arginine were 240 ± 14, 6.2 ± 0.6, and 42 ± 2.9 μmol · kg−1 · h−1, respectively (P < 0.01). Plasma turnover of citrulline derived from glutamine was shown to be 5.1 ± 0.7 μmol · kg−1 · h−1, and arginine derived from citrulline was shown to be 4.9 ± 0.9 μmol · kg−1 · h−1 (P < 0.01). The contribution of plasma glutamine to plasma arginine derived from plasma citrulline was calculated to be 64%. The kidneys were observed to take up >50% of circulating plasma citrulline and to release equimolar amounts of arginine into plasma. Conclusions: This study shows that glutamine is an important precursor for the synthesis of arginine in humans. It also provides a firm basis for future studies exploring the effect of a treatment dose and the route of administration (enteral or parenteral) of glutamine.

22 February 2005 in Hepatology
Verified
Journal Article
Open access
PDF file
MSMichiel P.C. Siroen
Michiel P.C. Siroen
JSJoost R. M. van der Sijp
Joost R. M. van der Sijp
TTTom Teerlink
Tom Teerlink
CSCors van Schaik
Cors van Schaik
RNRobert J. Nijveldt
Robert J. Nijveldt
PLPaul A. M. van Leeuwen
Paul A. M. van Leeuwen
Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) inhibit production of nitric oxide. The concentration of both dimethylarginines is regulated by urinary excretion, although ADMA, but not SDMA, is also subject to degradation by dimethylarginine dimethylaminohydrolase, which is highly expressed in the liver but also present in the kidney. The exact roles of the human liver and kidney in the metabolism of dimethylarginines are currently unknown. Therefore, we aimed to investigate renal and hepatic handling of ADMA and SDMA in detail in 24 patients undergoing hepatic surgery. To calculate net organ fluxes and fractional extraction (FE) rates, blood was collected from an arterial line, the portal vein, hepatic vein, and renal vein, and blood flow of the hepatic artery, portal vein, and renal vein was determined using Doppler ultrasound techniques. Results showed a significant net uptake (median [IQR]) of ADMA in both the liver (9.6 nmol/min [5.6–13.2]) and the kidney (12.1 nmol/min [1.3–17.1]). SDMA uptake was present not only in the kidney (12.7 nmol/min [3.5–25.4]), but also in the liver (7.7 nmol/min [2.8–16.4]). FE rates of ADMA for the liver and kidney were 5.0% (3.5%–7.4%) and 8.4% (1.3%–13.9%), respectively. For SDMA, hepatic and renal FE rates were 3.4% (2.1%–7.5%) and 12.5% (3.6%–16.2%), respectively. In conclusion, this study gives a detailed description of the hepatic and renal elimination of dimethylarginines and shows that the clearing of SDMA is not only confined to the kidney, but the human liver also takes up substantial amounts of SDMA from the portal and systemic circulation. (HEPATOLOGY 200541:559–565.)